© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Antibiotics, NSAIDs Reported Most Common Cause of Pediatric Anaphylaxis
March 18, 2025
Among pediatric patients aged 1 month to 18 years with emergent anaphylaxis, cephalosporins were the leading antibiotics and ibuprofen the top NSAID implicated in a new study.
Osteoporosis Risk Screening Tools Fall Short in Younger Postmenopausal Women, New Research Reveals
March 18, 2025
Three of the 5 osteoporosis screening tools recommended by the USPSTF for identifying osteoporosis in postmenopausal women aged 50 yo 64 years proved suboptimal.
Antihistamines Are a Poor Option to Treat Eczema in Older Adults: Clinical Pearl
March 18, 2025
Antihistamines for itch caused by disorders like atopic dermatitis pose more problems, like sedation and fall risk, than they provide relief, according to Daniel Butler, MD.
Povorcitinib Efficacy in 2 Pivotal Phase 3 Trials Will Support Global Regulatory Submission for Hidradenitis Suppurativa
March 17, 2025
Both trials met their primary endpoints, demonstrating a statistically significant improvement in HiSCR50 compared to placebo, with a favorable safety profile, according to Incyte.
Misdiagnosis of Migraine Drives Unnecessary Use of Health Care Resources
March 17, 2025
A new study compared health care utilization and costs between adults initially misdiagnosed followed by a correct diagnosis of migraine and those whose first diagnosis was accurate.
Daniel Butler, MD, a Leader in Geriatric Dermatology, Says Focus on the Overlap in the Etiology of Itch in Older Adults
March 17, 2025
AAD 2025: Tracing the multiple pathways that contribute to chronic itch vs looking for a singular cause helps optimize choice of therapy, Butler says.
Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits
March 14, 2025
A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.
Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use
March 14, 2025
Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.
Upadacitinib Demonstrates Superior Regional, Overall Efficacy vs Dupilumab in Atopic Dermatitis: Level Up Phase 3b/4 Trial Findings
March 14, 2025
Dupilumab-treated participants with recalcitrant head and neck symptoms who were switched to upadacitinib rapidly reached EASI 75 and steadily improved, among other findings.
FDA Submission Planned for Nonopioid Cebranopadol Following Positive Phase 3 Results: Tris Pharma Update
March 13, 2025
Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.